Ceramides contribute to
obesity-linked
insulin resistance and
inflammation in vivo, but whether this is a cell-autonomous phenomenon is debated, particularly in muscle, which dictates whole-body
glucose uptake. We comprehensively analyzed
lipid species produced in response to
fatty acids and examined the consequence to
insulin resistance and pro-inflammatory pathways. L6 myotubes were incubated with BSA-adsorbed
palmitate or
palmitoleate in the presence of
myriocin,
fenretinide, or
fumonisin B1.
Lipid species were determined by lipidomic analysis.
Insulin sensitivity was scored by Akt phosphorylation and
glucose transporter 4 (GLUT4) translocation, while pro-inflammatory indices were estimated by IκBα degradation and
cytokine expression.
Palmitate, but not
palmitoleate, had mild effects on Akt phosphorylation but significantly inhibited
insulin-stimulated GLUT4 translocation and increased expression of pro-inflammatory
cytokines Il6 and Ccl2
Ceramides, hexosylceramides, and
sphingosine-1-phosphate significantly heightened by
palmitate correlated negatively with
insulin sensitivity and positively with pro-inflammatory indices. Inhibition of
sphingolipid pathways led to marked changes in cellular
lipids, but did not prevent
palmitate-induced impairment of
insulin-stimulated GLUT4 translocation, suggesting that
palmitate-induced accumulation of deleterious
lipids and
insulin resistance are correlated but independent events in myotubes. We propose that muscle cell-endogenous
ceramide production does not evoke
insulin resistance and that deleterious effects of
ceramides in vivo may arise through ancillary cell communication.